Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | EIF4E | P06730 | 4/20 | 0.47 |
| ▸ | EIF4EBP1 | Q13541 | 4/20 | 0.47 |
| ▸ | KRAS | P01116 | 4/20 | 0.47 |
| ▸ | MDM4 | O15151 | 4/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16975610 | 0.96 | MDM4 (0.43) | MCL1ESR1EIF4EEIF4EBP1KRAS | |
| SCHEMBL14947860 | 0.94 | MDM4 (0.43) | MCL1ESR1EIF4EEIF4EBP1KRAS | |
| SCHEMBL14947863 | 0.89 | ESR1 (0.40) | MCL1ESR1EIF4EEIF4EBP1KRAS | |
| SCHEMBL14948248 | 0.89 | ESR1 (0.40) | MCL1ESR1EIF4EEIF4EBP1KRAS | |
| SCHEMBL15183813 | 0.70 | MDM2 (0.66) | ESR1EIF4EEIF4EBP1MDM4MDM2 | |
| SCHEMBL16975828 | 0.69 | ESR1 (0.34) | MCL1ESR1EIF4EEIF4EBP1MDM4 | |
| SCHEMBL14950915 | 0.69 | EIF4E (0.38) | MCL1ESR1EIF4EEIF4EBP1MDM4 | |
| SCHEMBL19760420 | 0.69 | ESR1 (0.52) | ESR1KRASMDM4MDM2ESR2 | |
| SCHEMBL17568833 | 0.65 | ESR1 (0.62) | MCL1ESR1EIF4EEIF4EBP1KRAS | |
| SCHEMBL17880428 | 0.65 | MAFG (0.53) | ESR1KRASESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096684-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | MCL1 677/4885ESR1 470/4885EIF4E 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.